Valuation: Zai Lab Limited

Market Cap 2.62B 44.85B 2.27B 2.12B 1.94B 3.65B 249B 3.71B 24.83B 9.73B 125B 9.84B 9.62B 413B P/E 2026 *
-12x
P/E 2027 * -12.4x
Enterprise Value 2.22B 38.08B 1.92B 1.8B 1.65B 3.1B 212B 3.15B 21.08B 8.26B 106B 8.35B 8.17B 351B EV / Sales 2026 *
5.24x
EV / Sales 2027 * 3.83x
Free-Float
95.17%
Yield 2026 *
-
Yield 2027 * -
3 years 270.64
Extreme 270.64
810
5 years 270.64
Extreme 270.64
2,446.85
10 years 270.64
Extreme 270.64
3,693.35
Manager TitleAgeSince
Chief Executive Officer 61 31/03/2014
Director of Finance/CFO 58 06/07/2023
President 62 30/11/2022
Director TitleAgeSince
Chairman 61 31/03/2014
Director/Board Member 83 31/12/2016
Director/Board Member 75 31/12/2016
Change 5-day change 1-year change 3-year change Capi.($)
+43.36%-.--% - - 2.35B
+1.59%+6.23%+41.29%+2.34% 77.1B
-0.84%+2.81%+22.05%+180.42% 49.43B
+2.77%+1.90%-1.84%+27.14% 49.27B
-0.13%+3.33%-50.97%-50.14% 44.59B
+0.80%+0.00%+60.77%-22.68% 30.48B
+1.84%-1.98%+55.26%+89.47% 24B
+9.86%+2.16%+121.53%-45.31% 21.5B
+4.29%+7.66%-3.26%+189.18% 20.18B
+1.66%-4.10%+68.10%+124.13% 16.29B
Average +5.55%+0.79%+34.77%+54.95% 36.98B
Weighted average by Cap. +1.49%+2.58%+26.27%+43.63%

Financials

2026 *2027 *
Net sales 425M 7.27B 367M 343M 315M 592M 40.43B 601M 4.02B 1.58B 20.26B 1.59B 1.56B 66.99B 584M 10B 506M 472M 433M 815M 55.64B 827M 5.54B 2.17B 27.88B 2.19B 2.15B 92.2B
Net income -211M -3.62B -183M -171M -157M -294M -20.11B -299M -2B -785M -10.07B -793M -776M -33.32B -160M -2.74B -138M -129M -119M -223M -15.22B -226M -1.52B -594M -7.63B -600M -587M -25.22B
Net Debt -396M -6.77B -342M -319M -293M -551M -37.65B -560M -3.75B -1.47B -18.86B -1.49B -1.45B -62.39B -381M -6.52B -330M -308M -282M -531M -36.25B -539M -3.61B -1.41B -18.16B -1.43B -1.4B -60.07B
Logo Zai Lab Limited
Zai Lab Ltd is a holding company primarily engaged in biopharmaceutical business. The Company is focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. The Company has a series of patented drug candidates from the discovery stage to the late clinical project, including ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others. The Company conducts its businesses within domestic and overseas markets.
Employees
1,784
Trader
Investor
-
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
20.88USD
Average target price
33.28USD
Spread / Average Target
+59.39%

Quarterly revenue - Rate of surprise